|
 |
Trial Results for MEM 3454 Alzheimer's Drug
(Source: Memory Pharmaceuticals) - Memory Pharmaceuticals announced positive results of Phase 2a testing of their experimental drug MEM 3454 for the treatment of mild to moderate Alzheimer's disease.
'Wall of Memories' Helps Alzheimer's Patients Preserve The Past
(Source: KTIV) - In honor of National Alzheimer's Disease Awareness Month, Siouxlanders are honoring their loved ones with AD.
When Is the Right Time to Stop Driving?
(Source: MITNews) - The MIT AgeLab announced the availability of new materials to help families and caregivers determine when it is time for loved ones with dementia to stop driving.
Is Long-term Cholinesterase Inhibitor Treatment of Alzheimer's Justified?
(Source: NCIB) - The cholinesterase inhibitors (ChEIs) donepezil, rivastigmine and galantamine are the current mainstays in the drug treatment of Alzheimer's disease.
Cost-Effectiveness of Memantine
(Source: NCIB) - In this study researchers at McMaster University analyzed cost-effectiveness data, comparing the addition of memantine to standard care (without acetylcholinesterase inhibitors) with standard care alone in moderate-to-severe Alzheimer disease.
Galantamine and Vasomotor Reactivity in Alzheimer's and Vascular Dementia
(Source: NCIB) - Recent reports suggest that vascular factors play a crucial role in the development and progression of Alzheimer's disease. In this study researchers at Friedrich-Schiller-University (Germany) assessed vasomotor reactivity [constriction or dilation of blood vessels] in patients with Alzheimer's disease and vascular dementia.
Alzheimer's Care Resources
(Source: Alzheimer's Association) - No one needs to be alone when managing care for someone with dementia. The Alzheimer's Association is offering an online suite of services to help you find and plan for care. Use them to widen your care options and help you cope with the challenges of Alzheimer's.
|
|